Search Results: (30 results)

This study aims to explore family communication differences across Asian American families  about testing positive for an inherited mutation in BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, TP53 or another gene linked to hereditary breast and/or ovarian cancer. Participants will complete a 10–15-minute initial intake survey to confirm eligibility. Eligible participants will then be contacted to schedule a 30-45-minute-long interview over Zoom to explore these topics. After completion of the interview, participants will be entered into a raffle for two $50 Visa gift cards. There are no costs associated with participation. NOTE: This study is closed. 

This study is looking at whether messaging and coaching can increase activity level and how moderate-to-vigorous activity improves symptoms and quality-of-life in women diagnosed with breast or endometrial cancer. NOTE: This study is no longer enrolling. 

Researchers at the Mayo Clinic, McGill University and FORCE are conducting a survey of women with a BRCA1/2 mutation, or who come from a family with a known BRCA mutation but tested negative, or have not had testing. Our goal is to learn about the information needs and decisions made related to endometrial cancer risk. https://tinyurl.com/BRCAMUTATION. NOTE: This study is closed for enrollment. 

This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.

The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women. NOTE: This study is no longer enrolling people

This study will look at how well atorvastatin (a cholesterol lowering agent) works with or without aspirin in preventing colorectal cancer in people with Lynch syndrome. Atorvastatin may lower the risk of developing cancers in the colon and rectum. Aspirin may reduce the risk of colon polyps and colon cancers. Giving atorvastatin and aspirin may work better at reducing the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.

This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage. 

This study is seeking information about the personal experiences of uterine and ovarian cancer prevention and screening for people with Lynch syndrome. An online survey will allow participants to share their experiences which will ultimately help medical practitioners be more aware about the wants, needs, and decision-making strategies used by people with Lynch syndrome to preserve their gynecological health.

This study is looking at the use of acupressure to manage cancer-related fatigue and sleep disturbances. EnergyPoints is an app that teaches users how to self-administer acupressure, to manage fatigue and sleep disturbances related to cancer. The purpose of this research study is to learn from participants’ experiences using EnergyPoints, while they wear a fitness tracker to measure activity and sleep.

This study is testing the effectiveness of adding a type of targeted therapy known as a PARP inhibitor to androgen-deprivation therapy for men with metastatic prostate cancer that has become resistant to standard androgen deprivation therapy.

Fear of cancer recurrence (FCR) is a common problem for breast cancer survivors. This study will test the effectiveness of three types of online, group therapy for breast cancer survivors with FCR. 

CA209-7FL: The purpose of a clinical trial is to look at whether the study drug, nivolumab, works in combination with neoadjuvant chemotherapy and adjuvant endocrine (hormone) therapy. The study will look at the safety profile of these study drug combinations and how well your body tolerates them. NOTE: This study is no longer enrolling patients. 

Researchers from the University of Illinois, Chicago Cancer Center invite breast cancer survivors who were diagnosed under the age of 45 to share their diagnosis stories. You will be asked to use your own words to share your experience on an online questionnaire. 

This study is comparing three different treatments for men with metastatic castration-resistant prostate cancer, (mCRPC) who also have an inherited mutation or a tumor mutation in a gene that affects DNA damage repair. The study is open to men with inherited mutations found on genetic testing or tumor mutations in one of the following genes: ATM, BRCA1, BRCA2, FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2, MSH6, BRIP1, or FAM175A.

Olaparib Expanded is a study looking at whether the drug Olaparib is effective treatment for people with certain types of metastatic breast cancer.  Olaparib belongs to a class of drugs known as PARP inhibitors. PARP inhibitors are particularly effective for treating tumors in people with an inherited BRCA mutation. This study is looking at whether olaparib is also effective for treating metastatic breast cancer in people who do not have an inherited BRCA mutation. Currently the study is only recruiting people with an inherited PALB2 mutation or people who test negative for an inherited mutation in BRCA1 or BRCA2 but have an acquired (somatic) BRCA1 or BRCA2 mutation found on tumor testing. 

The goal of AMPLITUDE is to see if adding the PARP inhibitor niraparib to standard of care hormone therapy (Abiraterone Acetate, prednisone and androgen deprivation therapy (ADT) is safe and more effective than standard of care alone. The study is enrolling people who have metastatic castration-sensitive prostate cancer and have an inherited or tumor mutation in one of the following genes involved in DNA damage repair: BRCA2, BRCA1, BRIP1, CHEK2, FANCA, PALB2, RAD51B and RAD54L. NOTE: This study is no longer enrolling patients. 

The goal of this study is to identify if there is a need for more specialized providers, specifically genetic counselors, to meet the needs of patients regarding fertility preservation and family planning prior to cancer treatment or preventative surgery. We hope to identify the appropriate setting and timeline for these services to streamline and enhance comprehensive patient care for patients with a hereditary breast or gynecologic cancer variant.

This study will survey individuals with a mutation in the BRCA1 or BRCA2 gene. We are seeking experiences and opinions of individuals regarding childbearing and reproductive choices. This will allow healthcare professionals, especially genetic counselors, to learn about what information is needed due to psychosocial and medical factors. The survey is approximately 25 minutes long to complete and is available online.

We are interviewing people who identify as Hispanic/Latinx/e with a genetic mutation associated with hereditary cancer and close family members who live in Latin America. This research study will describe genetic testing barriers and the communication of genetic risk to family members living in a Latin American country. The goal of this study is to improve the support that cancer genetic counselors can offer to individuals and their international family members. NOTE: This study is no longer enrolling. 

The goal of this research study is to determine if online genetic education and testing with online telephone genetic counseling is an acceptable method of delivering genetic testing to men with metastatic prostate cancer.

This study involves undergoing genetic counseling and genetic testing for inherited cancer risk.

This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals. 

The goal of this study is to compare the effectiveness of three different drug combinations to treat men with metastatic castration-resistant prostate cancer (mCRPR), who also have a mutation in a gene that affects DNA repair found through tumor testing. 

The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a nationwide clinical study comparing two FDA approved radiation therapies for the treatment of breast cancer, PHoton Therapy vs. PRoton Therapy. With any radiation treatment to the breast, the heart may be exposed to radiation potentially resulting in heart problems in the future. Both Photon and Proton therapies are FDA approved; however, to date doctors do not know which therapy is better or worse in terms of reducing side effects and promoting length and quality of life after radiation.

We hope to learn: The effectiveness of proton vs. photon therapy in reducing major cardiovascular events and how treatment affects patient’s quality of life, such as financial burden, fatigue, and anxiety. These objectives were chosen as study priorities by breast cancer patients themselves.

This study aims to explore perceptions of patients and genetic counselors about long-term follow-up in cancer genetic counseling, including if and how patients would like additional follow-up with a genetic counselor beyond the pre- and post-test counseling session. If you wish to participate, email the student investigator to schedule a voluntary 30–60-minute Zoom interview. All information will be de-identified. There are no costs associated with participation. NOTE: This study is no longer enrolling. 

We would like to invite you to share your experiences to help improve the quality of life for Asian Americans diagnosed with metastatic cancer. NOTE: This study is no longer enrolling. 

Global Patients along with IQVIATM, a worldwide healthcare consulting firm, is currently conducting a research study, to better understand the experience of patients and/or caregivers of patients living with metastatic pancreatic cancer.

Researchers at MD Anderson Cancer Center are conducting telephone interviews with individuals who have received modified (also known as reclassified or amended) genetic test results in any cancer related gene. We are interested in learning about the experience of receiving a modified test result and decisions made. 

This is a study on how the practice of crowdfunding affects the experience of having cancer. With the support of the National Science Foundation (NSF award #2021152), the researcher is interviewing cancer patients/survivors and their supporters about their use of crowdfunding platforms like GoFundMe. earcher is interviewing cancer patients/survivors and their supporters about their use of crowdfunding platforms like GoFundMe. 

You are invited to participate in an anonymous online survey about your decision to do genetic testing and how you dealt with the uncertainty of the outcome. The online survey includes a newly developed Uncertainty Management Scale (UMS) based on our years of prior uncertainty research. Knowing more about how people manage uncertainty may be helpful to society. You will be compensated $10 for completing the survey. This study is no longer enrolling. 

This study is looking at how to improve access to genetic testing among Hispanic/Latino populations in the U.S. We are conducting interviews with people in the Hispanic/Latino community who have either received genetic testing for hereditary cancer risk, or who have a family history of hereditary cancer and/or cancer diagnosis. This study could help develop policy options to inform how to improve access to genetic testing. Email Amanda Gutierrez at [email protected] if you are interested in participating. NOTE: This study is no longer enrolling.